Researchers at the Harry Perkins Institute and The University of Western Australia found that honeybee venom and its main molecule, melittin quickly destroys two aggressive forms of breast cancer, triple-negative and HER2-enriched, while sparing healthy breast cells.
Melittin breaks open the outer membrane of the cancer cell within an hour and, almost at once, shuts down key growth signals such as EGFR and HER2 that drive the disease.
When melittin was combined with the standard drug docetaxel in mice, tumour growth fell even further, suggesting the peptide can open the cell so other treatments work better.
The team warns that more work is needed to learn the safest dose and best way to deliver melittin before any human tests can begin, but the study shows nature may hold a new tool against hard-to-treat breast cancers.
Honeybee venom and melittin suppress growth factor receptor activation in HER2-enriched and triple-negative breast cancer – npj Precision Oncology, 1 September 2020. DOI: 10.1038/s41698-020-00129-0.
Open-access laboratory study showing that honeybee venom and synthetic melittin selectively kill aggressive breast-cancer cells, block EGFR/HER2 signalling and boost docetaxel in a mouse model.
Honeybee venom kills breast cancer cells – Harry Perkins Institute of Medical Research, 2 September 2020.
Press release summarising the findings and explaining how melittin was tested on different breast-cancer subtypes with minimal harm to normal cells.
Honeybee venom found to kill aggressive breast cancer cells – The University of Western Australia, 2 September 2020.
University news item quoting lead author Dr Ciara Duffy, emphasising the speed and selectivity of melittin and its potential use alongside chemotherapy.
Honeybee venom kills aggressive breast cancer cells – Medical News Today, 7 September 2020.
Popular-science article that places the work in context, noting earlier research on bee-venom therapy and stressing that clinical trials are still needed.
0 Comments